drugset / Trial / NCT05594758
Named Patient Program for Olverembatinib (HQP1351)
Summary
This program will allow eligible patients access to Ascentage Pharma's novel drug candidate Olverembatinib (approved in China) on a named patient basis in over 100 countries ( with the exception of the USA and China) and regions where the drug is not available.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Olverembatinib | Small molecule | — | Oral |
Indications
No indication recorded.